Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients

Louis Cantor, Darrell WuDunn, Yara Catoira-Boyle, Chi Wah Yung

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PURPOSE: To determine and compare the human aqueous humor (AH) concentrations of 2 formulations of brimonidine ophthalmic solution [0.1% brimonidine Purite (BP) (average pH 7.4 to 8.0) and 0.15% BP (average pH 6.6 to 7.4)]. PATIENTS AND METHODS: Single-center, randomized, controlled, double-masked, prospective study. Twenty-two patients were randomized to receive one 30-μL drop of 0.1% (n=11) or 0.15% BP (n=11) into the eye requiring routine cataract surgery. Solutions were administered approximately 40 to 55 minutes before surgery and AH samples (100 μL) were withdrawn from treated eyes at surgery initiation. Times from instillation to sampling were recorded. Brimonidine AH concentrations were assayed by high performance liquid chromatography-tandem mass spectrometry. RESULTS: Mean brimonidine AH concentrations sampled 52±9 and 54±8 minutes (P=0.57) after instillation of 0.1% and 0.15% BP solutions were 59.4±42.7 and 95.5±87.5 ng/mL, respectively (P=0.23). When normalized for concentration differences between the 2 formulations, AH concentrations were similar (P=0.85). Both solutions were well tolerated with no adverse events observed. CONCLUSIONS: Brimonidine AH concentrations in human eyes after single doses of 0.1% or 0.15% BP ophthalmic solutions were proportional to the respective concentrations of the brimonidine formulation instilled. The pH difference between these 2 formulations seemed to exert no effect on brimonidine bioavailability or the tolerability of the solution.

Original languageEnglish
Pages (from-to)529-534
Number of pages6
JournalJournal of Glaucoma
Volume17
Issue number7
DOIs
StatePublished - Oct 2008

Fingerprint

Aqueous Humor
Ophthalmic Solutions
Cataract
Brimonidine Tartrate
Tandem Mass Spectrometry
Double-Blind Method
Biological Availability
High Pressure Liquid Chromatography
Prospective Studies

Keywords

  • Brimonidine
  • Cataract patients
  • Ophthalmic solutions

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients. / Cantor, Louis; WuDunn, Darrell; Catoira-Boyle, Yara; Yung, Chi Wah.

In: Journal of Glaucoma, Vol. 17, No. 7, 10.2008, p. 529-534.

Research output: Contribution to journalArticle

@article{9b3a7f53f824408ca49347b5f6cc3ffb,
title = "Absorption of brimonidine 0.1{\%} and 0.15{\%} ophthalmic solutions in the aqueous humor of cataract patients",
abstract = "PURPOSE: To determine and compare the human aqueous humor (AH) concentrations of 2 formulations of brimonidine ophthalmic solution [0.1{\%} brimonidine Purite (BP) (average pH 7.4 to 8.0) and 0.15{\%} BP (average pH 6.6 to 7.4)]. PATIENTS AND METHODS: Single-center, randomized, controlled, double-masked, prospective study. Twenty-two patients were randomized to receive one 30-μL drop of 0.1{\%} (n=11) or 0.15{\%} BP (n=11) into the eye requiring routine cataract surgery. Solutions were administered approximately 40 to 55 minutes before surgery and AH samples (100 μL) were withdrawn from treated eyes at surgery initiation. Times from instillation to sampling were recorded. Brimonidine AH concentrations were assayed by high performance liquid chromatography-tandem mass spectrometry. RESULTS: Mean brimonidine AH concentrations sampled 52±9 and 54±8 minutes (P=0.57) after instillation of 0.1{\%} and 0.15{\%} BP solutions were 59.4±42.7 and 95.5±87.5 ng/mL, respectively (P=0.23). When normalized for concentration differences between the 2 formulations, AH concentrations were similar (P=0.85). Both solutions were well tolerated with no adverse events observed. CONCLUSIONS: Brimonidine AH concentrations in human eyes after single doses of 0.1{\%} or 0.15{\%} BP ophthalmic solutions were proportional to the respective concentrations of the brimonidine formulation instilled. The pH difference between these 2 formulations seemed to exert no effect on brimonidine bioavailability or the tolerability of the solution.",
keywords = "Brimonidine, Cataract patients, Ophthalmic solutions",
author = "Louis Cantor and Darrell WuDunn and Yara Catoira-Boyle and Yung, {Chi Wah}",
year = "2008",
month = "10",
doi = "10.1097/IJG.0b013e318162257f",
language = "English",
volume = "17",
pages = "529--534",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients

AU - Cantor, Louis

AU - WuDunn, Darrell

AU - Catoira-Boyle, Yara

AU - Yung, Chi Wah

PY - 2008/10

Y1 - 2008/10

N2 - PURPOSE: To determine and compare the human aqueous humor (AH) concentrations of 2 formulations of brimonidine ophthalmic solution [0.1% brimonidine Purite (BP) (average pH 7.4 to 8.0) and 0.15% BP (average pH 6.6 to 7.4)]. PATIENTS AND METHODS: Single-center, randomized, controlled, double-masked, prospective study. Twenty-two patients were randomized to receive one 30-μL drop of 0.1% (n=11) or 0.15% BP (n=11) into the eye requiring routine cataract surgery. Solutions were administered approximately 40 to 55 minutes before surgery and AH samples (100 μL) were withdrawn from treated eyes at surgery initiation. Times from instillation to sampling were recorded. Brimonidine AH concentrations were assayed by high performance liquid chromatography-tandem mass spectrometry. RESULTS: Mean brimonidine AH concentrations sampled 52±9 and 54±8 minutes (P=0.57) after instillation of 0.1% and 0.15% BP solutions were 59.4±42.7 and 95.5±87.5 ng/mL, respectively (P=0.23). When normalized for concentration differences between the 2 formulations, AH concentrations were similar (P=0.85). Both solutions were well tolerated with no adverse events observed. CONCLUSIONS: Brimonidine AH concentrations in human eyes after single doses of 0.1% or 0.15% BP ophthalmic solutions were proportional to the respective concentrations of the brimonidine formulation instilled. The pH difference between these 2 formulations seemed to exert no effect on brimonidine bioavailability or the tolerability of the solution.

AB - PURPOSE: To determine and compare the human aqueous humor (AH) concentrations of 2 formulations of brimonidine ophthalmic solution [0.1% brimonidine Purite (BP) (average pH 7.4 to 8.0) and 0.15% BP (average pH 6.6 to 7.4)]. PATIENTS AND METHODS: Single-center, randomized, controlled, double-masked, prospective study. Twenty-two patients were randomized to receive one 30-μL drop of 0.1% (n=11) or 0.15% BP (n=11) into the eye requiring routine cataract surgery. Solutions were administered approximately 40 to 55 minutes before surgery and AH samples (100 μL) were withdrawn from treated eyes at surgery initiation. Times from instillation to sampling were recorded. Brimonidine AH concentrations were assayed by high performance liquid chromatography-tandem mass spectrometry. RESULTS: Mean brimonidine AH concentrations sampled 52±9 and 54±8 minutes (P=0.57) after instillation of 0.1% and 0.15% BP solutions were 59.4±42.7 and 95.5±87.5 ng/mL, respectively (P=0.23). When normalized for concentration differences between the 2 formulations, AH concentrations were similar (P=0.85). Both solutions were well tolerated with no adverse events observed. CONCLUSIONS: Brimonidine AH concentrations in human eyes after single doses of 0.1% or 0.15% BP ophthalmic solutions were proportional to the respective concentrations of the brimonidine formulation instilled. The pH difference between these 2 formulations seemed to exert no effect on brimonidine bioavailability or the tolerability of the solution.

KW - Brimonidine

KW - Cataract patients

KW - Ophthalmic solutions

UR - http://www.scopus.com/inward/record.url?scp=58149335188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149335188&partnerID=8YFLogxK

U2 - 10.1097/IJG.0b013e318162257f

DO - 10.1097/IJG.0b013e318162257f

M3 - Article

C2 - 18854728

AN - SCOPUS:58149335188

VL - 17

SP - 529

EP - 534

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 7

ER -